MarketView

MarketView

RXA MarketView enables pharmaceutical companies to analyse the current prescribing of a new or potential product and help to develop a market entry strategy.

The tool provides comprehensive analysis for both NHS and pharmaceutical companies of the UK prescribing market, giving valuable insight down to CCG level.

With the RXA MarketView tool you can:

  • Analyse up to 5 years of NHS prescribing and other sales data
  • See data for all 20,000+ products prescribed by UK GPs, including branded and generic products
  • See data for England, Wales, Scotland and Northern Ireland
  • Select a range of reporting dimensions and filters
    • SHA
    • Area/CCG
    • GP Practice
    • Product
    • Brand vs. Generic
  • View extensive highly visual tables, charts and maps in the purpose-built dashboard
  • Access easy to interpret analytics
  • Export all data and graphics for ad-hoc analytics and report building – (E.g. Excel, CSV, jpeg and PDF)
We make analytics simple
Request your demonstration today

“I am regularly told by my sales team that Inspiremed’s software is one of the best tools in sales, measurement and planning that they’ve ever used.”

National Sales Manager, Leading UK Pharmaceutical Company

“Customers tell us our platform has changed the way they work, that they’ve enhanced the strategies they implement, based on the work they’ve done with the analyser tool and that – bottom line – we’ve helped them to increase their sales. That’s a pretty good result from a chance cup of coffee.”

Andrew Norman and David Warwick, Directors

“Inspiremed’s customer service is personal, swift and attentive.”

National Sales Manager, UK Pharmaceutical Company

“I am extremely happy with the model and with the working relationship we have with Inspiremed.”

Country Manager UK, Leading Diagnostics Company

“Rx Analyser is already having a significant impact on our business, allowing our Territory Managers to focus on established CCG accounts and identify practice level successes and others for further development.”

Managing Director, UK Diabetes Healthcare Company

“The budget impact models are a real benefit.”

National Sales Manager, UK Pharmaceutical Company

Sign up for added insights